Liver Cancer After Two TACE Failures: Naming a Procedure That Has Stopped Helping
A defined clinical criterion exists for exactly this moment — and naming it out loud is harder than it sounds when the procedure that's failing is also the one everyone in the room knows how to do well.
R.J., a 70-year-old man, spent his career as a machinist and still tinkers with small-engine repairs for neighbors, work that keeps his hands busy in ways he says matter more to him now than they used to. His intermediate-stage, multinodular hepatocellular carcinoma — five lesions confined to the liver, Child-Pugh A, no vascular invasion — was treated with transarterial chemoembolization eight months ago with a good initial response, and again four months ago after new nodules appeared, this time with only partial, incomplete tumor response by mRECIST criteria in more than half the treated lesions. Today's follow-up imaging, six weeks after the second procedure, shows the same pattern: some necrosis, but persistent viable, enhancing tumor in three of five lesions, plus one new small nodule outside the previously treated field.
TACE refractoriness is a defined clinical concept, not just a subjective sense that a procedure "isn't working as well anymore": the Japan Society of Hepatology / Liver Cancer Study Group of Japan criteria (Kudo et al.) describe it as an inadequate response — more than half the treated tumor volume remaining viable — across two or more consecutive, adequately performed TACE procedures, or the appearance of new lesions despite embolization of the prior nodules, either of which R.J.'s imaging arguably already meets. The reason the criteria exist at all is that repeated TACE in genuinely refractory disease does not just fail to control tumor — it progressively worsens liver function with each procedure, potentially foreclosing him from later systemic therapy or transplant candidacy by the time the group finally agrees the liver-directed approach has run its course. The awkward part is the mismatch in what each measure has registered so far: the refractoriness criteria are already met on imaging, while the liver-function cost they exist to prevent shows up only as a falling albumin and has not yet moved him off Child-Pugh A.
Liver tumor board, reviewing second TACE follow-up imaging
I'd do a third session. Two of his five lesions did show real necrosis, and I've had patients achieve durable control after a second or even third round when the first two showed partial response rather than outright progression. The new nodule is small and in an accessible location. I don't think one incomplete response, or even two, automatically means the procedure has stopped working for him specifically.
I hear that some lesions responded, but the JSH-LCSGJ refractoriness criteria (Kudo et al.) are specifically built around this pattern — more than half of treated tumor volume remaining viable across two consecutive, adequately performed procedures, or a new lesion appearing despite treatment. He meets both. Those criteria weren't written to second-guess good procedural work — they exist because repeated embolization in genuinely refractory disease costs liver function without buying tumor control, and his albumin is already trending the wrong way.
I'm not disputing that some of this disease responded to TACE — I'm saying the pattern across two full procedures is exactly what the refractoriness definition was written to capture, not an edge case we get to interpret around.
I'd frame the new nodule as a separate question from the refractory disease in the previously treated lesions. A narrow, targeted procedure for that one new spot is a reasonable, low-burden addition — but it shouldn't come at the cost of starting systemic therapy for the rest of his disease. His albumin trend tells me his liver has already absorbed real cost from two rounds; I'd rather add one small, targeted intervention than commit to another full refractory-pattern TACE session while systemic therapy waits.
Agreed: systemic therapy with atezolizumab and bevacizumab started for the TACE-refractory disease, alongside one narrowly targeted procedure for the single new isolated nodule rather than a full repeat embolization of the previously treated field.
The interventional radiologist's clinical read — that some lesions still showed real, meaningful response — was not disputed as inaccurate, only judged insufficient against the refractoriness criteria met across the full pattern. Liver function and albumin trend will be followed closely alongside tumor response now that systemic therapy has started.